News | November 14, 2022
Suven Life Sciences posts Q2FY23 consolidated loss at Rs. 23.18 Cr
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
Suven Life Sciences has reported total income of Rs. 3.97 crores during the period ended June 30, 2022
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Casper Pharma is a Hyderabad based SEZ company engaged in the formulations business. Post-purchase of shares, the target entity would become a wholly-owned subsidiary of SPL
Suven Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
Postal ballot also clears remuneration proposal and new ESOP 2026 scheme, strengthening the company’s leadership and talent retention strategy
Nearly 1.43 crore families in West Bengal to benefit as India’s flagship health assurance scheme achieves full national coverage across all States and Union Territories
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
